Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,737 | 95.55 | 4,17,028.41 | 705.44 | 0.92 | 5,651.21 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,408.5 | 66.17 | 1,70,237.04 | 598 | 0.47 | 2,578 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,333.3 | 65.73 | 1,46,800.71 | 577 | 0.14 | 2,547 | 249.82 |
Cipla Ltd CIPLA | 1,348.2 | 23.76 | 1,08,860.56 | 616.88 | 1.19 | 4,256.93 | 411.55 |
Dr Reddys Laboratories Ltd DRREDDY | 1,286.3 | 23.16 | 1,07,435.25 | 90.6 | 0.62 | 4,266.4 | 377.55 |
The European business reported a 54 percent year on year surge in topline during the quarter.
Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.
The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.
Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.
Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.
Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.
Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
